Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

Elevated liver enzymes forced the Swiss biotech to halt a development of its lead compound in chronic indications, but the company insists a back-up shows promise.

You may also be interested in...



Addex Extends Its Runway With CHF 20 Million Investment By BVF

Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.

Addex Extends Its Runway With CHF 20 Million Investment By BVF

Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.

Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing

After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.

Related Content

Topics

UsernamePublicRestriction

Register

PS068879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel